Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.35 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77054 | 0.84 | IDO1 (0.41) | IDO1CYP3A4MAPTTSHRALDH1A1 | |
| SCHEMBL9954933 | 0.82 | DPP4 (0.44) | NPFFR1NPFFR2IDO1CYP3A4MAPT | |
| SCHEMBL14999534 | 0.81 | IDO1 (0.38) | IDO1CYP3A4MAPTTSHRMAOA | |
| SCHEMBL15824244 | 0.81 | DPP4 (0.43) | NPFFR1NPFFR2IDO1CYP3A4MAPT | |
| SCHEMBL14690574 | 0.75 | IDO1 (0.38) | IDO1CYP3A4MAPTTSHRTAAR1 | |
| SCHEMBL4082174 | 0.73 | CYP3A4 (0.41) | NPFFR1NPFFR2IDO1CYP3A4MAPT | |
| SCHEMBL1187758 | 0.73 | IDO1 (0.39) | NPFFR1NPFFR2IDO1CYP3A4MAPT | |
| SCHEMBL29360870 | 0.73 | MAOA (0.38) | IDO1CYP3A4MAPTTSHRMAOA | |
| SCHEMBL16846917 | 0.73 | — | — | |
| SCHEMBL17829152 | 0.72 | SMN1; SMN2 (0.36) | CYP3A4MAPTDPP4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229805-B1 | SPIROCYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-10221186-B2 | Spirocyclic heterocyclic compounds useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170334924-A1 | Spirocyclic Heterocyclic Compounds Useful As HIV Integrase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170334924-A1 | Spirocyclic Heterocyclic Compounds Useful As HIV Integrase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-23 | — | — | US | disclosed |
| WO-2016094197-A1 | SPIROCYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016090545-A1 | SPIROCYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRATE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334924-A1 | Spirocyclic Heterocyclic Compounds Useful As HIV Integrase Inhibitors | CCNY, CDKN1A, RPIA | NPFFR1 3030/4885NPFFR2 4147/4885IDO1 665/4885 |
| US-10221186-B2 | Spirocyclic heterocyclic compounds useful as HIV integrase inhibitors | CCNY, CDKN1A, RPIA | NPFFR1 3030/4885NPFFR2 4147/4885IDO1 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.